You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis
SBC: GLYCOMIRA, LLC Topic: NIAIDPROJECT SUMMARY Chronic rhinosinusitis (CRS) is one of the most prevalent inflammatory diseases in the U.S., affecting up to 16% of the population and substantially diminishing the quality of life and productivity of patients. In four years, the annual U.S. health care expenditure to treat patients with CRS dramatically increased from $9B to $64B (5% of the health care budget), with a correspondin ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Mechanism underpinning synergy with combined treatment of MTI-101 and Dexamethasone in Multiple Myeloma
SBC: MODULATION THERAPEUTICS, INC. Topic: NCIABSTRACT Multiple myeloma (MM) is the second most common hematopoietic cancer and while survival rates have slowly increase in the last 10 years, the five-year survival is just over 50%. The high number of patients that become refractory to current therapies is the core reason for the low long-term survival. Therefore, there is a crucial need to develop unique drugs that are active in refractory a ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Novel SCD1 inhibitors for treatment of cancer
SBC: MODULATION THERAPEUTICS, INC. Topic: 102Project Summary Metabolic reprogramming plays a critical role in carcinogenesisin part due its ability to promote immune suppressive properties within tumorsHoweverit is unclear whether inhibition of fatty acid metabolism in tumors affects their immunogenicityHerewe show for the first time that inhibition of stearoyl CoA desaturaseSCDthe rate limiting enzyme involved in fatty acid synthesis conver ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Large Pore SPP Particles for Protein Separations
SBC: ADVANCED MATERIALS TECHNOLOGY, INC. Topic: 400AbstractLife sciences research and other critical bioanalytical applications would strongly benefit from faster and higher resolution high performance liquid chromatographicHPLCseparations of larger molecules including proteinspeptidesglycopeptidesand glycansProteins therapeutics are complex moleculessusceptible to intended or unintended alterations of composition and conformationMany therapeutic ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Enhanced Recovery of Pharmaceutical Solvent driven by EPA Initiative
SBC: COMPACT MEMBRANE SYSTEMS, INC. Topic: NIEHSSummary Enhanced Recovery of Pharmaceutical Solvent driven by EPA InitiativeThe United States Environmental Protection AgencyEPAis establishing new safeguards for hazardous secondary materials with objectives to promote the economicenvironmentaland public health benefits of recycling wasteswith an emphasis on several industrial sectorsincluding the pharmaceutical industryOn averagepharmaceutical m ...
SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Robust Predictor of Colon Cancer Risk
SBC: Morgan and Mendel Genomics, Inc. Topic: 102Summary At leastpeople in the United States are at high risk for Lynch syndromebased on inheritance of a genetic mutation in the mismatch repairMMRor double strand breakDSBrepair pathwayMore than half of them are unaware of their riskbecause their family history is uninformative or unknownGenetic testing is important for identifying mutations in this pathwaybut in a large number of cases no mutati ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of an a MC1R selective companion diagnostic imaging probe
SBC: MODULATION THERAPEUTICS, INC. Topic: 102The melanocortinreceptorMC Ris over expressed on uveal and cutaneous melanoma cellsbut notin healthy normal tissuesWe have developed a proprietary ligandMTIthat binds to MC R inmelanoma cells with high affinity and specificityThrough our SBIR Phase I contractwedemonstrated that MC R targetedAc DOTA MTIlacks of overt toxicity at single doses thatproduce significant efficacy against uveal and cutane ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
A Combined High-Throughput Single-Cell Transcriptomic and Secretomic Assay for Neurodegenerative Disease Biomarker Discovery
SBC: ISOPLEXIS CORPORATION Topic: 105In this Phase I application IsoPlexis proposes to deliver a novel method for targeted profiling of both the transcriptome and secretome from an array ofsingle central and peripheral immune cellsSpecificallywe will deliver a single cellmRNA and secreted protein capture assay with proven sensitivity for detecting the most important predictive biomarkers for neurodegenerative diseasesThere is growing ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Single-cell Phosphoprotein Assay to Evaluate Brain Tumor Therapeutic Resistance
SBC: ISOPLEXIS CORPORATION Topic: 102Although signal transduction inhibitors occasionally offer clinical benefit for cancer patientssignal flux emanating from oncogenes is often distributed through multiple pathwayspotentially underlying the resistance which causes failure of most such inhibitorsMeasuring signal flux through multiple pathwaysin response to signal transduction inhibitorsmay help uncover network interactions that contr ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
A High-Throughput, Multi-Omic Assay of Tumor Biomarkers from Single-Cells
SBC: ISOPLEXIS CORPORATION Topic: 172SUMMARY Although solid tumors oftentimes arise from the uninhibited growth of a single aberrant cellthe population of cells within a tumor are genetically and molecularly heterogenousThis makes it very difficult to evaluate a therapy s efficacy when using bulk population measurementsFurthermorerecent research has implicated microRNAsmiRNAsas drivers of progression and malignancy in many tumor type ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health